SEOUL, Nov. 26 (Xinhua) -- The South Korean government may not go on with its plan to purchase a vaccine for the A/H1N1 virus made by GlaxoSmithKline Plc. (GSK), the South Korean unit of the Britain-based pharmaceutical company said Thursday.

    According to the GSK, the South Korean government has not yet shown intention to buy GSK's "Aprepanrix" although it earlier signed a letter of intent with the company to secure 3 million doses of the vaccine within the year.

    "There have been disagreements over the terms of the agreement, and the government has so far shown no sign of continuing with the deal further," said Yang Su-jin, an official at the company's communications division.

    South Korean health authorities have recently been saying there is no need to bring in foreign vaccines, as the country is able to produce enough domestically.

    In the meantime, Aprepanrix went under an investigation in Canada as at least six cases of anaphylactic shock, which refers to a severe allergic reaction that could lead to respiratory failure and respiratory arrest, were found to be related to the vaccine.

    Followingly, the vaccine was recalled in the North American country.　

Special Report:  World Tackles A/H1N1 Flu